Table 3.

Adjusted analysis with survival after re-LTx as main outcome parameter (n=135). Center includes the 4 different centers of re-LTx, to guarantee anynomousity of the patients and centers, the reference center is not displayed. The reference for gender is male. Regarding admission status, the reference status is admitted, while BOS is the reference for CLAD phenotype.

	Total study population HR(CI)	rCLAD HR(CI)	BOS HR(CI)
Center
1 vs. 0	3.53(1.94–8.08)	5.29(1.14–24.59)	4.86(1.46–16.14)**
2 vs. 0	1.25(0.60–2.61)	2.27(0.67–7.64)	1.16(0.33–4.06)
3 vs. 0	2.02(0.85–4.82)	2.24(0.56–10.26)	1.48(0.39–5.60)
Gender (male vs. fem)	1.00(0.57–1.74)	1.09(0.37–3.23)	0.95(0.37–2.42)
Age at re-LTx	1.02 (0.99–1.04)	0.98 (0.94–1.03)	1.02(0.95–1.06)
Native disease
COPD vs. CF	1.84(0.77–4.43)	18.66(2.17–160.46)**	1.03(0.32–3.34)
ILD vs. CF	1.40(0.63–3.14)	4.12(0.96–17.62)	1.50(0.50–4.57)
Other vs. CF	1.18(0.52–2.70)	2.72(0.51–14.62)	1.33(0.47–3.78)
CLAD phenotype (BOS vs. RAS)	2.61(1.51–4.51)***	NA	NA
BMI	0.96 (0.89–1.04)	0.85 (0.74–0.99)*	1.10(0.95–1.25)
Admission status (admitted vs. home)	0.40 (0.23–0.72)**	0.30(0.12–0.75)*	0.39(0.17–1.01)

^*p<0.05,

^**p<0.01,

^***p<0.001.